Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 3/20 | 0.77 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.51 |
| ▸ | METAP2 | P50579 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250104 | 0.88 | GRK2 (0.67) | GRK2GRM2 | |
| SCHEMBL12743472 | 0.87 | GRK2 (0.78) | GRK2GRM2 | |
| SCHEMBL12743418 | 0.87 | GRK2 (1.00) | GRK2GRM2 | |
| SCHEMBL12743414 | 0.87 | GRK2 (0.70) | GRK2GRM2 | |
| SCHEMBL13947149 | 0.86 | GRK2 (0.76) | GRK2GRM2 | |
| SCHEMBL8255227 | 0.85 | GRK2 (0.61) | GRK2GRM2 | |
| SCHEMBL8251793 | 0.83 | GRK2 (0.71) | GRK2GRM2METAP2 | |
| SCHEMBL8253701 | 0.82 | GRK2 (0.67) | GRK2 | |
| SCHEMBL8253714 | 0.82 | GRK2 (0.61) | GRK2GRM2 | |
| SCHEMBL8250074 | 0.81 | GRK2 (0.60) | GRK2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2021046225-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-7910602-B2 | treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| US-7910602-B2 | treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| EP-1899333-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1 | SANOFI AVENTIS (FR) | 2009-02-18 | — | — | EP | disclosed |
| US-20080227777-A1 | Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-20080227777-A1 | Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| WO-2007000241-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1 | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227777-A1 | Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 | ADRB1, ADRB3, ADRB2 | GRK2 29/4885GRM2 1694/4885METAP2 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.